Axa S.A. Fibrogen Inc Transaction History

Axa S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$15.95 - $25.18 $92,510 - $146,044	-5,800 Reduced 18.35%	25,800 $481,000
Q4 2022 Feb 14, 2023	SELL	$13.27 - $17.73 $2.38 Million - $3.18 Million	-179,100 Reduced 85.0%	31,600 $506,000
Q2 2022 Aug 15, 2022	BUY	$7.94 - $12.96 $1.67 Million - $2.73 Million	210,700 New	210,700 $2.23 Million
Q2 2018 Aug 13, 2018	SELL	$44.9 - $64.95 $273,890 - $396,195	-6,100 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$45.35 - $61.65 $276,635 - $376,065	6,100 New	6,100 $282,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.